Shares of Johnson & Johnson (NYSE:JNJ) ended Monday session in green amid volatile trading. The shares closed up +1.55 points or 1.35% at $116.66 with 6.40 million shares getting traded. Post opening the session at $115.89, the shares hit an intraday low of $115.84 and an intraday high of $116.72 and the price vacillated in this range throughout the day. The company has a market cap of $317.84 billion and the numbers of outstanding shares have been calculated to be 2.72 billion shares.
Johnson & Johnson (JNJ) recently declared that its Board of Directors has declared a cash dividend for the fourth quarter of 2016 of $0.80 per share on the company’s common stock. The dividend is payable on December 6, 2016 to shareholders of record at the close of business on November 22, 2016. The ex-dividend date is November 18, 2016.
Shares of Celgene Corporation (NASDAQ:CELG) ended Monday session in green amid volatile trading. The shares closed up +4.05 points or 3.92% at $107.49 with 6.45 million shares getting traded. Post opening the session at $104.86, the shares hit an intraday low of $104.72 and an intraday high of $108.00 and the price vacillated in this range throughout the day. The company has a market cap of $83.87 billion and the numbers of outstanding shares have been calculated to be 775.20 million shares.
Celgene Corporation (CELG) and IBM Watson Health (NYSE: IBM) recently declared a partnershipto co-develop IBM Watson for Patient Safety, a new offering that aims to enhance pharmacovigilance methods used to collect, assess, monitor, and report adverse drug reactions. The new offering will run on the Watson Health Cloud.
The partnershipwill combine Watson’s cognitive computing ability with Celgene’s deep history and experience in drug safety and risk administration in order to create an outcome- and evidence-based drug safety decision support system for life science companies. Watson’s cognitive computing engine continuously learns, so it is expected that Watson for Patient Safety will increasingly be able to assist identify potential drug safety signals.
Watson for Patient Safety is being developed as a first-of-its-kind, highly automated drug-safety offering designed to facilitate the rapid collection, collation and automated analysis of high volumes of data from diverse sources, counting anonymized electronic medical records, medical claims databases and other healthcare information sources. Watson for Patient Safety will be designed to drive pharmaceutical companies’ understanding of complex safety questions, and delivery of evidence-based insights to assist support ongoing understanding of the safety profiles of drug products by stakeholders.